

Dabigatran etexilate hard capsules

PRESCRIBER GUIDE

for primary prevention of venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

This prescriber guide does not substitute the dabigatran etexilate Summary of Product Characteristics,^{1,2} which may be accessed at www.medicines.org.uk/emc/

Date of preparation: February 2024 | Version 1.0 | Approved by MHRA: April 2024

CONTENTS

• Patient Alert Card and counselling	p2
• Indication	p2
• Contraindications	p2
• Dosing	p3
• Special patient populations potentially at higher risk of bleeding	p6
• Perioperative management	p8
• Coagulation tests and their interpretation	p9
• Overdose	p11
• Management of bleeding complications	p11



PATIENT ALERT CARD AND COUNSELLING

A Patient alert card is provided to your patient in the dabigatran package. The patient should be instructed to carry the Patient alert card at all times and present it when seeing a healthcare provider. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.



INDICATION^{1,2}

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery (pVTEp).



CONTRAINDICATIONS^{1,2}

- Hypersensitivity to the active substance or to any of the excipients
- Severe renal impairment (creatinine clearance [CrCL] <30 mL/min)
- Active clinically significant bleeding
- Lesion or condition, if considered a significant risk factor for major bleeding. This may include:
 - current or recent gastrointestinal ulceration
 - presence of malignant neoplasms at high risk of bleeding
 - recent brain or spinal injury

- recent brain, spinal or ophthalmic surgery
- recent intracranial haemorrhage
- known or suspected oesophageal varices
- arteriovenous malformations
- vascular aneurysms or major intraspinal or intracerebral vascular abnormalities

- Concomitant treatment with any other anticoagulant agent e.g.
 - unfractionated heparin (UFH)
 - low molecular weight heparins (enoxaparin, dalteparin etc.)
 - heparin derivatives (fondaparinux etc.)
 - oral anticoagulants (warfarin, rivaroxaban, apixaban etc.)

except under specific circumstances. These are switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation

- Hepatic impairment or liver disease expected to have any impact on survival
- Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole, cyclosporine, itraconazole, dronedarone and the fixed-dose combination glecaprevir/pibrentasvir
- Prosthetic heart valves requiring anticoagulant treatment

**RECOMMENDED DAILY DOSE TAKEN AS
2 CAPSULES OF 110 MG ONCE DAILY^{1,2}**

DABIGATRAN
220mg

	Treatment initiation on day of surgery 1-4 hours after completed surgery	Maintenance dose starting on the first day after surgery	Duration of maintenance dose
Patients following elective knee replacement surgery	Single capsule of 110 mg dabigatran	220 mg dabigatran once daily taken as 2 capsules of 110 mg	10 days
Patients following elective hip replacement surgery			28-35 days

Please note: If haemostasis in the post-operative phase is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery, then treatment should be initiated with 2 capsules once daily.

DOSE REDUCTION

LOWER DAILY DOSE FOR SPECIAL POPULATIONS
TAKEN AS 2 CAPSULES OF 75 MG ONCE DAILY^{1,2}



	Treatment initiation on day of surgery 1-4 hours after completed surgery	Maintenance dose starting on the first day after surgery	Duration of maintenance dose
Patients with moderate renal impairment (creatinine clearance (CrCL) 30–50 mL/min)	Single capsule of 75 mg dabigatran	150 mg dabigatran once daily taken as 2 capsules of 75 mg	10 days (knee replacement surgery) or 28–35 days (hip replacement surgery)
Patients who receive concomitant verapamil, amiodarone, quinidine			
Patients aged 75 or above			

In patients with both moderate renal impairment and concomitantly treated with verapamil, a dose reduction of dabigatran to 75 mg once daily should be considered.



RECOMMENDATION FOR KIDNEY FUNCTION MEASUREMENT IN ALL PATIENTS

- Renal function should be assessed by calculating the CrCL by the Cockcroft-Gault* method **prior to initiation of treatment with dabigatran** to exclude patients with severe renal impairment (i.e. CrCL <30 mL/min)
- Renal function should also be assessed when a decline in renal function is suspected **during treatment** (e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products)

*Cockcroft-Gault formula

For creatinine in mg/dL

$$\frac{(140 - \text{age [years]}) \times \text{weight [kg]} (\times 0.85 \text{ if female})}{72 \times \text{serum creatinine [mg/dL]}}$$

For creatinine in $\mu\text{mol/L}$

$$\frac{1.23 \times (140 - \text{age [years]}) \times \text{weight [kg]} (\times 0.85 \text{ if female})}{\text{serum creatinine [\mu mol/L]}}$$


SWITCHING^{1,2}

Dabigatran treatment to parenteral anticoagulant

It is recommended to wait 24 hours after the last dose before switching from dabigatran to a parenteral anticoagulant.



Last dose of dabigatran




Wait 24 hrs



Start injectable anticoagulant and stop dabigatran

Parenteral anticoagulant to dabigatran

The parenteral anticoagulant should be discontinued and dabigatran started 0-2 hours prior to the time that the next dose of the alternate therapy would be due, or at the time of discontinuation in case of continuous treatment (e.g. intravenous Unfractionated Heparin (UFH)).



Method of administration

Dabigatran is for oral use.

- The capsules can be taken with or without food. Dabigatran should be swallowed whole with a glass of water, to facilitate delivery to the stomach
- Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding
- Dabigatran should be stored in original packaging in order to protect from moisture



SPECIAL PATIENT POPULATIONS POTENTIALLY AT HIGHER RISK OF BLEEDING^{1,2}

Patients with an increased bleeding risk (see Table 1) should be closely monitored for signs or

symptoms of bleeding or anaemia, especially if risk factors are combined. An unexplained fall in haemoglobin and/or haematocrit or blood pressure should lead to a search for a bleeding site. A coagulation test (see section on Coagulation tests and their interpretation) may help to identify patients with an increased bleeding risk caused by excessive dabigatran exposure. When clinically relevant bleeding occurs, treatment should be interrupted.

For situations of life-threatening or uncontrolled bleeding, when rapid reversal of the anticoagulation effect of dabigatran is required, the specific reversal agent idarucizumab is available.¹⁰

Table 1*: Factors which may increase the haemorrhagic risk

Pharmacodynamic and kinetic factors	Age ≥75 years
Factors increasing dabigatran plasma levels	Major: • Moderate renal impairment (30–50 mL/min CrCL)[†] • Strong P-gp[†] inhibitor co-medication (see section Contraindications) • Mild to moderate P-gp inhibitor co-medication (e.g. amiodarone, verapamil, quinidine and ticagrelor) Minor: • Low body weight (<50 kg)
Pharmacodynamic interactions	• Acetylsalicylic acid and other platelet aggregation inhibitors such as clopidogrel • NSAIDs[‡] • SSRIs or SNRIs[#] • Other medicinal products which may impair haemostasis
Diseases/procedures with special haemorrhagic risks	• Congenital or acquired coagulation disorders • Thrombocytopenia or functional platelet defects • Oesophagitis, gastritis, gastroesophageal re lux • Recent biopsy, major trauma • Bacterial endocarditis

* For special patient populations requiring a reduced dose, see section Dosing.

[†] CrCL: Creatinine clearance; P-gp: P-glycoprotein.

[‡] NSAIDs: non-steroidal anti-inflammatory drugs

[#] SSRIs: selective serotonin re-uptake inhibitors; SNRIs: serotonin norepinephrine re-uptake inhibitors.



PERIOPERATIVE MANAGEMENT

Surgery and interventions

Patients on dabigatran who undergo surgery or invasive procedures are at increased risk for bleeding. Therefore, surgical interventions may require the temporary discontinuation of dabigatran.

Clearance of dabigatran in patients with renal insufficiency may take longer. This should be considered in advance of any procedures. Please see also section 'SPECIAL PATIENT POPULATIONS POTENTIALLY AT HIGHER RISK OF BLEEDING' on page 6.

Emergency surgery or urgent procedures

Dabigatran should be temporarily discontinued. When rapid reversal of the anticoagulation effect of dabigatran is required the specific reversal agent idarucizumab to dabigatran is available.¹⁰

Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease.

Dabigatran treatment can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate haemostasis has been achieved.

Subacute surgery / interventions

Dabigatran should be temporarily discontinued. A surgery/intervention should be delayed if possible until at least 12 hours after the last dose. If surgery cannot be delayed the risk of bleeding may be increased. This risk of bleeding should be weighed against the urgency of intervention.

Elective surgery

If possible, dabigatran should be discontinued at least 24 hours before invasive or surgical procedures.

In patients at higher risk of bleeding or in major surgery where complete haemostasis may be required, consider stopping dabigatran 2-4 days before surgery. For discontinuation rules see Table 2.

Table 2: Discontinuation rules before invasive or surgical procedures

Renal function (CrCL mL/min)	Estimated half-life (hours)	Stop dabigatran before elective surgery	
		High risk of bleeding or major surgery	Standard risk
≥ 80	~13	2 days before	24 hours before
≥50 – <80	~15	2–3 days before	1–2 days before
≥30 – <50	~18	4 days before	2–3 days before (>48 hours)

**Spinal anaesthesia/epidural anaesthesia/
lumbar puncture**

Procedures such as spinal anaesthesia may require complete haemostatic function. The risk of spinal or epidural haematoma may be increased in cases of traumatic or repeated puncture and by the prolonged use of epidural catheters. After removal of a catheter, an interval of at least 2 hours should elapse before the administration of the first dose of dabigatran. These patients require frequent observation for neurological signs and symptoms of spinal or epidural haematoma.



**COAGULATION TESTS
AND THEIR INTERPRETATION³**

Dabigatran treatment does not need routine anticoagulant monitoring.^{4,5} In cases of suspected overdose or in patients treated with dabigatran presenting in emergency departments or prior to surgery, it may be advisable to assess the anticoagulation status. The available test methods are described as follows. For further details, please refer to the Summary of Product Characteristics.

- **International Normalised Ratio (INR)**
The INR test is unreliable in patients on dabigatran and should not be performed.
- **Activated Partial Thromboplastin Time (aPTT)**
The aPTT test provides an approximate indication of the anticoagulation status but is not suitable for precise quantification of anticoagulant effect.
- **Dilute Thrombin Time (dTT), Thrombin Time (TT), Ecarin Clotting Time (ECT)**
There is a close correlation between plasma dabigatran concentration and degree of

anticoagulant effect.^{1–3} For a quantitative measurement of dabigatran plasma concentrations, several dabigatran calibrated assays based on dTT have been developed.^{6–9} A diluted TT measure (dTT) of **>67 ng/mL dabigatran plasma concentration prior to the next medicinal product intake** may be associated with a higher risk of bleeding.^{1,2} A normal dTT measurement indicates no clinical relevant anticoagulant effect of dabigatran. TT and ECT may provide useful information, but the tests are not standardised.

Table 3: Coagulation test thresholds at trough (i.e. prior to the next medicinal product intake) that may be associated with an increased risk of bleeding.^{1,2} Please note: in the first 2–3 days after surgery there may be greater test variability therefore results should be interpreted with caution.^{3,4}

Test (trough value)	
dTT [ng/mL]	>67
ECT [x-fold upper limit of normal]	No data*
aPTT [x-fold upper limit of normal]	>1.3
INR	Should not be performed

* The ECT was not measured in patients treated for prevention of VTEs after hip or knee replacement surgery with 220 mg dabigatran once daily.

Time point: Anticoagulant parameters depend on the time when the blood sample was taken as well as when the last dose was given. A blood sample taken 2 hours after dabigatran ingestion (~peak level) will have different (higher) results in all clotting tests compared with a blood sample taken 20–28 hours (trough level) after ingestion of the same dose.



OVERDOSE ¹⁻³

In cases where overdose is suspected, coagulation tests may help to assess the bleeding risk.

Excessive anticoagulation may require interruption of dabigatran. Since dabigatran is excreted predominantly by the renal route, adequate diuresis must be maintained. As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies. Dabigatran overdose may lead to haemorrhage. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated (see section Management of bleeding complications). General supportive measures such as application of oral activated charcoal may be considered to reduce absorption of dabigatran.

MANAGEMENT OF BLEEDING COMPLICATIONS ^{1-3,10}

For situations when rapid reversal of the anticoagulant effect of dabigatran is required (life-threatening or uncontrolled bleeding or for emergency surgery/urgent procedures) the specific reversal agent idarucizumab is available.

Depending on the clinical situation appropriate standard treatment, e.g., surgical haemostasis and blood volume replacement should be undertaken. Consideration may be given to the use of fresh whole blood, fresh frozen plasma and/or platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet medicinal products have been used. Coagulation factor concentrates (activated or non-activated) or recombinant Factor VIIa may be taken into account. However, clinical data are very limited.

The recommendations given in this prescriber guide only refer to the use of dabigatran in primary prevention of VTE following total hip or knee replacement surgery with once-daily dosing.

References

1. Glenmark Pharmaceuticals Europe Ltd. Dabigatran etexilate 110 mg hard capsules Summary of Product Characteristics. 2. Glenmark Pharmaceuticals Europe Ltd. Dabigatran etexilate 75 mg hard capsules Summary of Product Characteristics. 3. van Ryn J et al. *Thromb Haemost* 2010; 103:1116–1127. 4. Liesenfeld K-H et al. *Br J Clin Pharmacol* 2006; 62:527–537. 5. Stangier J et al. *Br J Clin Pharmacol* 2007; 64:292–303. 6. Hemoclot thrombin inhibitor assay (Hyphen BioMed, Neuville-sur Oise, France). www.hyphen-biomed.com 7. HemosIL assay (Instrumentation Laboratory, Werfen Group, Barcelona, Spain). www.instrumentationlaboratory.com 8. Technoclot DTI Dabigatran assay (Technoclone GmbH, Vienna, Austria). www.technoclone.com 9. INNOVANCE® DTI Assay (Siemens Healthineers GmbH, Erlangen, Germany). <https://www.healthcare.siemens.com/hemostasis> 10. Pollack C et al. *NEJM* 2015; 373:511–20.

REPORTING ADVERSE EVENTS AND QUALITY COMPLAINTS

Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website
www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd.

If you want to report an adverse event or product quality complaint, reports can be directed via email to **Medical_information@glenmarkpharma.com** or by telephoning Glenmark Medical Information team on **0800 458 0383**.



DABIGATRAN

PRESCRIBER GUIDE

Date of preparation: February 2024
Version 1.0 | Approved by MHRA: April 2024